AB BioTechnologies, Inc. (AB) is a contract development and manufacturing organization (CDMO) located in Bloomington, Indiana, USA. In 2008, formulation and lyophilization expert Dr. J. Jeff Schwegman, Ph.D. founded the company as a teaching and consulting firm. Under his guidance, the company’s offerings have greatly expanded by readily adjusting to client demand with added services, capabilities, instrumentation, and laboratory space. Relied upon by organizations of all sizes, AB is an internationally renowned leader in lyophilization and formulation development for small and large molecules, suspensions, emulsions, and diagnostic products. AB offers corresponding process development and analytical services as supplements and standalone projects. AB BioTechnologies' clients receive the dedicated attention of scientists who understand the critical science of each formulation, enabling them to clear the hurdles of manufacturing with ease. From early-stage development work to pre-clinical / tox studies material manufacture, AB BioTechnologies' experienced scientists bring client projects from concept to clinic.
AB’s contract services support early-stage development and provide pre-clinical / tox manufacturing to clients around the world. They have conducted numerous formulation and lyophilization seminars and lectures in Europe, China, India, and throughout the United States. AB’s knowledgeable scientists perform pre-formulation and formulation development services and have the tools and expertise to develop and optimize lyophilization cycles, offering differential scanning calorimetry (DSC), freeze-dry microscopy, and lyo cycle scale-up and transfer. With the recent addition of GLP manufacturing to their portfolio, AB can now shorten the time to the clinic by offering liquid and lyophilized vial filling.